Treatment is based on the cause of the<unk>  and may include laser therapy to the retina. Laser photocoagulation therapy has been the standard treatment for many types of<unk> . Evidence shows that laser therapy is generally safe and improves visual symptoms in sickle cell and diabetic<unk> . In recent years targeting the pathway controlling vessel growth or angiogenesis has been promising. Vascular endothelial growth factor (VEGF) seems to play a vital role in promoting neovascularization. Using anti-VEGF drugs (antibodies to sequester the growth factor), research have shown significant reduction in the extent of vessel outgrowth. Low quality evidence supports the use of anti-VEGF antibodies, such as bevacizumab or pegaptanib which seems to improve outcomes when used in conjunction with laser therapy to treat<unk>  of prematurity, longer term systemic effects are not known however. The evidence is poorer for treatment of diabetic<unk> . Use of anti-VEGF drugs did not appear to improve outcomes when compared to standard laser therapy for diabetic<unk> .
Retinopathy
Maculopathy
Optic neuropathy
Peripheral neuropathy
Color blindness
Arthropathy
Retinal degeneration 
Ocular hypertension